StockData
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. (MRKR) stock

MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/30
$0.84+0.01 (+0.97%)

Close on Nov 17, 2026Market cap $13.95MP/E –Yield –

Marker Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Marker Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$9.76M. For fiscal 2025 it was -$12.01M. The highest annual figure on record is -$694.58K in fiscal 2013.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.01M–
FY2024Dec 31, 2024-$10.91M–
FY2023Dec 31, 2023-$16.44M–
FY2022Dec 31, 2022-$26.97M–
FY2021Dec 31, 2021-$27.28M–
FY2020Dec 31, 2020-$20.03M–
FY2019Dec 31, 2019-$18.28M–
FY2018Dec 31, 2018-$14.48M–
FY2017Dec 31, 2017-$8.44M–
FY2016Dec 31, 2016-$6.51M–
FY2015Dec 31, 2015-$4.34M–
FY2014Dec 31, 2014-$2.19M–
FY2013Dec 31, 2013-$694.58K–
FY2012Dec 31, 2012-$1.59M–
FY2011Dec 31, 2011-$1.31M–
FY2010Dec 31, 2010-$925.04K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.72M–
Q1 FY2026Mar 31, 2026-$1.40M–
Q4 FY2025Dec 31, 2025-$1.90M–
Q3 FY2025Sep 30, 2025-$2.74M-328.5%
Q2 FY2025Jun 30, 2025-$1.88M–
Q1 FY2025Mar 31, 2025-$5.50M–
Q4 FY2024Dec 31, 2024-$4.70M–
Q3 FY2024Sep 30, 2024$1.20M–
Q2 FY2024Jun 30, 2024-$3.57M–
Q1 FY2024Mar 31, 2024-$3.84M–
Q4 FY2023Dec 31, 2023-$2.37M–
Q3 FY2023Sep 30, 2023-$1.13M–
Q2 FY2023Jun 30, 2023-$7.06M–
Q1 FY2023Mar 31, 2023-$5.89M–
Q4 FY2022Dec 31, 2022-$6.31M–
Q3 FY2022Sep 30, 2022-$7.65M–
Q2 FY2022Jun 30, 2022-$794.71K–
Q1 FY2022Mar 31, 2022-$12.23M–
Q4 FY2021Dec 31, 2021-$4.86M–
Q3 FY2021Sep 30, 2021-$7.54M–
Q2 FY2021Jun 30, 2021-$6.79M–
Q1 FY2021Mar 31, 2021-$8.10M–
Q4 FY2020Dec 31, 2020-$5.50M–
Q3 FY2020Sep 30, 2020-$6.13M–
Q2 FY2020Jun 30, 2020-$4.30M–
Q1 FY2020Mar 31, 2020-$4.10M–
Q4 FY2019Dec 31, 2019-$4.56M–
Q3 FY2019Sep 30, 2019-$5.66M–
Q2 FY2019Jun 30, 2019-$4.18M–
Q1 FY2019Mar 31, 2019-$3.88M–
Q2 FY2018Jun 30, 2018-$2.40M–
Q1 FY2018Mar 31, 2018-$2.35M–
Q4 FY2017Dec 31, 2017-$2.48M–
Q3 FY2017Sep 30, 2017-$2.03M–
Q2 FY2017Jun 30, 2017-$2.01M–
Q1 FY2017Mar 31, 2017-$1.92M–
Q4 FY2016Dec 31, 2016-$1.75M–
Q3 FY2016Sep 30, 2016-$1.97M–
Q2 FY2016Jun 30, 2016-$1.95M–

More Marker Therapeutics figures

See a number that looks wrong?